within Pharmacolibrary.Drugs.ATC.L;

model L04AC08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.66,
    Cl             = 0.0029,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Canakinumab is a human monoclonal antibody targeting interleukin-1 beta (IL-1Î²), used in the treatment of autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (sJIA), and Still's disease. It is an approved immunosuppressive agent, primarily administered to reduce inflammation.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult and pediatric patients with autoinflammatory conditions. Data from observed clinical trials including healthy volunteers and patients with CAPS.</p><h4>References</h4><ol><li>Pascal Richette, Aline Frazier, Thomas Bardin,Pharmacokinetics considerations for gout treatments.,Expert opinion on drug metabolism & toxicology,2014<a href='https://pubmed.ncbi.nlm.nih.gov/24809930/'>https://pubmed.ncbi.nlm.nih.gov/24809930/</a></li><li>Naomi Schlesinger,Canakinumab in gout.,Expert opinion on biological therapy,2012<a href='https://pubmed.ncbi.nlm.nih.gov/22784099/'>https://pubmed.ncbi.nlm.nih.gov/22784099/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC08;
